[ A21-152] Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V
Last updated 20.05.2022
Project no.: A21-152
Commission: Commission awarded on 29.11.2021 by the Federal Joint Committee (G-BA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Haematology
Add-on therapy for adult patients with inadequately controlled hypereosinophilic syndrome (HES) without an identifiable non-haematological secondary cause
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2022-05-20 A G-BA decision was published.